Bristol-Myers Squibb
(BMY)Financial Overview
About Bristol-Myers Squibb
Bristol-Myers Squibb, under CEO Christopher Boerner, is a global biopharmaceutical company focused on oncology, immunology, cardiovascular, and fibrosis. Known for drugs like Opdivo, Eliquis, and Revlimid, the company has a strong pipeline of innovative treatments. Under Boerner’s leadership, BMS is advancing in cell therapy and precision medicine. The company continues to expand access to life-saving therapies worldwide. It remains a key player in cancer and chronic disease treatment.
Analyst Forecast
Bristol-Myers Squibb is navigating a difficult patent cliff but leaning into oncology and immunology for growth. Opdivo and Eliquis remain strong performers, though generics loom. The acquisition of Karuna Therapeutics signals a push into neuroscience. Cost-cutting and share buybacks are helping support EPS. New drug launches will be critical in the coming 24 months. A mixed bag with medium-term catalysts and long-term challenges.
Analysis by Luigi Wewege
President at Caye International Bank
Luigi Wewege is President of the award-winning Caye International Bank. He is the author of The Digital Banking Revolution, now in its third edition, and of the article “Disruptions and Digital Banking Trends,” published in The Journal of Applied Finance & Banking. Luigi has also co-authored economic research examining the accuracy of credit bureau data, which was presented before the United States Congress. At Caye Bank, his research and strategic insights help guide billions in client portfolio decisions across international markets. Known for his disciplined diversification philosophy, he served as the conceptual architect behind this Portfolio Fit Calculator. He holds an Italian MBA specializing in International Business, and earned his BSBA with a triple major in Finance, International Business, and Management, graduating with Latin Honors from the University of Missouri–St. Louis.
18 years of experience
Should You Buy Bristol-Myers Squibb Stock?
This interactive tool helps you determine whether this stock fits into your investment strategy based on your portfolio size, risk tolerance, and allocation preferences.
What this calculator analyzes:
- Risk compatibility between your profile and this stock
- Appropriate allocation size for your portfolio
- Diversification recommendations
- P/E ratio context and valuation analysis
Example Analysis:
A 21.8 P/E ratio indicates this stock has a moderate valuation. With a Low risk rating, this stock may be suitable for conservative portfolios.
⚠️ This tool is for informational purposes only. It does not constitute financial advice. Investing involves risk, including loss of capital. Always consult a licensed financial advisor before making investment decisions.